Indeed, previous studies have shown that gliomas with IDH1 mutation had a better response to treatment with chemotherapeutic agent temozolomide (Houillier et al., 2010; Hartmann et al., 2011; Kim and Liau, 2012; SongTao et al., 2012; Yang et al., 2015), indicating the role of IDH1 mutation as a predictive marker. This evidence concerns the gene IDH1 and central nervous system cancer.